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Abstract 
While follicular lymphoma (FL) is exquisitely responsive to immuno-chemotherapy, many patients 
follow a relapsing remitting clinical course driven in part by a common precursor cell (CPC) 
population. Advances in next generation sequencing have provided valuable insights into the 
genetic landscape of FL and its clonal evolution in response to therapy, implicating perturbations of 
epigenetic regulators as a hallmark of the disease. Recurrent mutations of histone modifiers 
KMT2D, CREBBP, EP300, EZH2, ARIDIA, and linker histones are likely early events arising in the 
CPC pool, rendering epigenetic based therapies conceptually attractive for treatment of indolent 
and transformed FL. This review provides a synopsis of the main epigenetic aberrations and the 
current efforts in development and testing of epigenetic therapies in this B cell malignancy. 
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Introduction 
Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphoma 
(NHL), accounting for over 20% of all NHL cases. The incorporation of the anti-CD20 monoclonal 
antibody, rituximab, into treatment regimens has led to considerable improvement in the outlook of 
FL patients with 5-year overall survival approaching 90%. However, many patients display a 
relapsing-remitting pattern, with the disease eventually becoming resistant to further therapy, 
representing a major area of unmet clinical need1. These patients include a high-risk subgroup 
(30% of patients) prone to transformation into a higher-grade lymphoma2, 3, and a poor-prognostic 
subgroup (20% of cases) who progresses or relapses within 2 years of receiving first line 
treatment1. 
 At the molecular level, 85%-90% of FL are characterized by the t(14;18) translocation, which 
places the anti-apoptotic proto-oncogene BCL2 under the transcriptional control of the IGH locus, 
leading to BCL2 overexpression4-7. Intriguingly, however, t(14;18) alone is not sufficient for 
malignant transformation as it can be detected in healthy individuals who never develop the 
disease8, 9; therefore, there has been a concerted effort to identify the additional “hits” that 
cooperate with t(14;18) to induce malignant transformation in GC B cells. Additionally, 10%-15% of 
FL cases do not harbor the t(14;18) translocation10, and the pathogenic mechanisms driving the 
development of this subset of FL remain largely unknown. 
The mutational landscape of follicular lymphoma 
FL originates from the germinal center (GC) within lymphoid tissues, where B cells undergo 
clonal expansion and extensive genetic modifications through the processes of somatic 
hypermutation and class switch recombination11. Genome-wide association studies12, cytogenetic 
analyses13-16, gene expression,17-19 and microRNA profiling20, 21 have highlighted chromosomal 
alterations, including 1p36 and 6q losses, components of the tumor microenvironment, and 
association with HLA gene variants, among others12, 22. The most significant shift in our 
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understanding of FL’s genetic landscape, however, has occurred following advances in next 
generation sequencing (NGS). These include mutations in genes involved in immune surveillance, 
B cell development, BCR-NFkB and JAK/STAT signaling pathways, with, perhaps most strikingly, 
the identification of a plethora of mutations in series of epigenetic modifiers, such as CREBBP, 
EP300, EZH2, KMT2D, MEF2B, several members of SWI/SNF nucleosome remodeling complex, 
including ARID1A, ARID1B and BCL7A, as well as members of the linker histone H1 and histone 
H2 gene families23-32 (Figure 1). Epigenetic deregulation has long been recognized as a cardinal 
feature of many solid and hematologic cancers and, thus far, four epigenetic drugs have been 
licensed for the treatment of hematologic malignancies33. However, what distinguishes FL is its 
apparent addiction to epigenetic alterations, with lesions in epigenetic modifiers occurring in nearly 
all patients25, 27, 34. By contrast, in diffuse large B cell lymphoma (DLBCL), a more aggressive form 
of NHL, mutations in epigenetic modifiers (CREBBP, EP300, EZH2, and KMT2D) occur in ~60% of 
the GC B cell (GCB)-like subtype, which shares a common cell of origin with FL, with fewer 
epigenetic mutations reported in the activated B cell (ABC)-like subtype24, 35, 36 and Burkitt 
lymphoma37, a rarer form of GC NHL. Intriguingly, epigenetic abnormalities are common in adult-
type FL, but are rarely found in pediatric-type nodal follicular lymphoma (PTNFL), a rare variant of 
t(14;18)-negative FL, where the mutational landscape is genetically light, featuring recurrent 
mutations in TNFRSF14 and MAPK signaling pathway genes38, 39. The infrequency of epigenetic 
aberrations and the distinctly more favorable prognosis in PTNFL compared to FL, including 
t(14;18)-negative FL, further supports the notion that epigenetic deregulation in adult-type FL 
pathogenesis may support the durability of lymphoma and the resultant clinical course of the 
disease. 
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Aberrations of epigenetic modifiers are early and driving events in the pathogenesis of 
follicular lymphoma 
There is emerging evidence that the later age onset of FL is due to accumulation of several 
oncogenic events within the long-lived B cell progenitors40-42. Studies based on temporal profiling of 
FL and transformed FL (tFL), in addition to rare examples of donor-derived FL occurring several 
years following allogeneic stem cell transplant and donor lymphocyte infusions where both patients 
shared the same IGH and IGH-BCL2 rearrangements and somatic mutations, lend credence to the 
existence of a long-lived pool of common progenitor cells (CPCs) acting as tumor-initiating cells that 
need to be eliminated in order to improve outcomes25, 27, 30, 43, 44. 
Transformation in FL arises predominantly by divergent evolution (reviewed in 42), rather 
than through sequential acquisition of genetic aberrations, with mutations affecting the epigenetic 
modifiers KMT2D, EZH2, CREBBP, and MEF2B, being commonly shared between FL and tFL 
samples. These mutations are typically clonal, supporting a founder role for these events in FL, 
while mutations in NFkB signaling pathway, B cell development, or cell cycle genes tend to occur 
as later events presumably leading to the emergence of fitter clones that drive disease progression 
and transformation. It is worth keeping in mind that individual mutations in epigenetic modifiers are 
potentially insufficient to give rise to FL, although there has been an intriguing case study of FL 
occurring in a patient with Rubinstein-Taybi syndrome, a developmental disorder linked to germline 
CREBBP mutations45. In a minority of cases, however, evolution through “sparse” CPCs occurs 
with little clonal resemblance between paired FL and tFL samples and presents different epigenetic 
mutations acquired independently25, 27, which is supported by a broad consensus in the literature 
through the contributions of several groups in the field. 
Role of epigenetic regulatory mutations in lymphomagenesis 
The potential roles of genetic aberrations affecting epigenetic modifiers in lymphomagenesis 
have been elucidated in a number of functional studies. Inactivating KMT2D mutations46, 47 and 
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gain-of-function EZH2 mutations (a member of Polycomb-group proteins), mainly at tyrosine 641 
(Y641) hotspot23, 28, 48, 49, promote GC proliferation and block differentiation by transcriptional 
suppression of tumor suppressor genes that regulate B cell development, including KMT2D targets 
TNFAIP3, SOCS3 and TNFRSF14 and EZH2 targets CDKN1A, CDKN2A, PRDM1, and IRF446, 50--
52. While it has long been assumed that mutations in epigenetic modifiers arise in GC, in vivo 
models have shown that the impact of KMT2D mutations is dependent on the stage of B cell 
development, whereby mutations in early precursor B cells are sufficient to initiate lymphoma while 
mutations arising at later stages of GC B cell development require additional genetic hits to support 
malignant transformation46, 47. Loss-of-function CREBBP mutations in FL have been shown to 
facilitate immune evasion by downregulating MHC class II expression, associated with reduced T 
cell infiltration53. These inactivating mutations may also contribute to lymphomagenesis by impairing 
the acetylation of non-histone proteins p53 and BCL626, with emerging data showing that the 
BCL6/HDAC3/SMRT complex maintain the suppression of CREBBP target genes, including MHC 
class II, in CREBBP-mutant cells, rendering HDAC3 inhibition as a potential therapeutic strategy by 
restoring histone H3 lysine 27 acetylation at target enhancers54. More recently, global DNA 
methylation analysis of follicular lymphoma B cells has revealed hypermethylation of Polycomb-
suppressed genes and hypomethylation of heterochromatin regions compared to normal GC B 
cells. The abnormal DNA methylation programming in FL may potentially cooperate with the 
underlying somatic mutations in, for example, chromatin modifiers to fixate the normal dynamic 
transcriptional regulation of B cell differentiation genes55. Furthermore, enhancer profiling of FL B 
cells has identified subsets of abnormally activated or repressed regulatory elements that may also 
contain somatic mutations that directly impact on transcription factor binding and transcriptional 
regulation of downstream genes, indicating another mode of aberrant epigenetic contribution to FL 
pathogenesis56. 
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Taken together, these lines of evidence demonstrate a pivotal role for epigenetic 
abnormalities, not only as initiating events but also as potential drivers of progression, 
transformation, and modulators of the tumor microenvironment. The particular enrichment of 
epigenetic lesions in the CPC population also underscores the potential of epigenetic therapies as 
means of eradicating the founder clone in FL. These experiments equally highlight the challenges 
faced in predicting the mechanisms by which these mutations exert their effects and whether each 
genetic lesion is acting alone or there is some concerted effort in shifting a B cell towards 
malignancy. 
Mutations in epigenetic modifiers can predict patient outcomes in FL 
FL patients who relapse within 2 years of receiving R-CHOP treatment present a significant 
clinical challenge. The follicular lymphoma international prognostic index (FLIPI)57 is useful to 
predict prognosis based on clinical and basic laboratory parameters; however, FLIPI tends to 
overestimate high-risk patients at diagnosis58 and cannot be used effectively to inform clinical 
decisions. Therefore, in recent years, there have been efforts to develop new experimental models, 
the first of which, m7-FLIPI, incorporates the mutational status of seven genes, including the five 
epigenetic modifiers EZH2, CREBBP, EP300, MEF2B, and ARID1A34. m7-FLIPI has been shown to 
be more effective at distinguishing between high- and low-risk FL patients measured by 5-year 
failure-free survival following first line R-CHOP, with almost half of the patients classified as high-
risk by FLIPI re-classified as low-risk by m7-FLIPI. This new prognostic tool is also more accurate in 
predicting disease progression within 24 months, a surrogate endpoint for overall survival, and in 
identifying the small subset of patients who are at the highest risk of early treatment failure following 
first line R-CHOP. Critically, high risk patients tend to carry CREBBP or EP300 mutations, while 
EZH2- or MEF2B-mutant cases are associated with low risk disease and favorable outcome34 and 
may benefit from less intensive R-CHOP regimens. However, it is still unclear how individual 
genetic lesions affect sensitivity to treatment (outcome predictors) or aggressiveness of the disease 
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(prognostic marker). Overall, the inclusion of epigenetic modifier mutations in patient risk 
stratification holds promise for more accurate prediction of patient outcomes following first line 
treatment with R-CHOP, although this needs further improvements in prospective studies before 
they can be translated into routine clinical practice. 
Epigenetic inhibitors in follicular lymphoma therapy 
Current treatment strategies for FL are based on a “one size fits all” approach that fails to 
take into account the specific genetic and epigenetic aberrations in different patients. Going 
forward, a more considered approach may be most beneficial for high risk patients who relapse 
within the first 2 years and the patients who transform to more aggressive lymphoma. The 
abundance and the co-founding role of epigenetic modifier mutations in indolent FL and tFL, 
together with the reversibility of epigenetic abnormalities, offer a platform to apply small molecule 
inhibitors that target these epigenetic aberrations in a precision medicine approach. 
Targeting gain-of-function EZH2 mutations as emerging epigenetic therapies 
EZH2 gain-of-function hotspot mutations are oncogenic drivers in 25% of FL patients that remain 
stable during disease relapse and/or transformation23, 25, 28, therefore providing a bona fide drug 
target for FL therapy. Several S-adenosylmethionine-competitive EZH2-selective inhibitors (EZH2i) 
have been developed in recent years, including GSK-126, EPZ-6438, and CPI-1205, with superior 
EZH2 selectivity over EZH1 and other histone methyltransferases. These EZH2i have shown 
significant inhibitory effects against EZH2-mutant lymphoma cell growth and survival in pre-clinical 
studies59-63 and are currently being tested in phase I/II clinical trials (Table 1). Preliminary trial 
results of EPZ-6438 [NCT01897571] in a small subset of B-NHL patients indicate 60% objective 
response (partial or complete response)64. While encouraging, the clinical efficacy of EZH2i awaits 
data in large series of patients accounted for the mutational status of EZH2 and cell of origin. The 
intriguing responses in EZH2 wild type patients may be caused by underlying genetic abnormalities 
such as inactivating mutations in H3K27 demethylase machinery60 or by targeting the EZH2’s non-
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enzymatic role consistent with findings in SWI/SNF-mutant cancers65, suggesting that epigenetic 
modifiers may cooperate in driving FL. Critically, however, identifying reliable diagnostic biomarkers 
for patients who will benefit from EZH2i therapy remains challenging. 
Based on recent studies, there is also the prospect of EZH2i as a means of eradicating 
cancer stem cells. This has been exemplified in chronic myeloid leukemia where leukemic stem 
cells, which are typically resistant to first-line tyrosine kinase inhibitors, are sensitive to EZH2i due 
to their abnormal EZH2 gain-of-function status66, 67. Therefore, it is worth testing the efficacy of 
EZH2i in targeting the subset of EZH2-mutant FL CPCs to prevent them repopulating subsequent 
disease relapses or transformation. 
HDAC inhibitors may benefit high-risk follicular lymphoma patients 
Loss-of-function mutations of CREBBP/EP300 leading to acetylation imbalance are 
associated with high-risk FL patients34, therefore providing a rationale for histone deacetylase 
inhibitors (HDACi) therapy for this patient category. A number of HDACi have been tested in cancer 
trials in recent years, with vorinostat, which is licensed for the treatment of advanced cutaneous T 
cell lymphoma68, being the most exhaustively tested orally bioavailable HDACi against lymphoid 
malignancies (Table 2). The efficacy of vorinostat against relapsed/refractory FL has been shown in 
phase I/II trials with an objective response rate of ~50%69, 70 and median progression free survival 
(PFS) of 30.5 months70. Interestingly, vorinostat has shown inferior efficacies against non-FL type 
B-NHLs, including mantle cell and marginal zone lymphomas that are deplete of acetylation-
compromising genetic lesions. There may be value, therefore, in correlating CREBBP/EP300 
mutation status with response to HDACi in order to identify patients most likely to derive benefit 
from these therapies. One case in point is the association of MEF2B mutations in DLBCL with 
response to the HDACi panobinostat, in a phase II trial71. Furthermore, a recent study in Kabuki 
syndrome, a congenital genetic disorder, has linked loss-of-function KMT2D mutations to sensitivity 
to HDACi72, a biomarker that can be investigated in future HDACi trials. There are also a number of 
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caveats limiting widespread application of epigenetic therapies. In the example of HDACi, the exact 
mechanism of action in patients is poorly understood, as they can exert their function by acetylating 
both histone and non-histone proteins that are implicated in several biological processes, including 
cell cycle73, DNA damage response, apoptosis74, 75, angiogenesis76, and regulation of tumor 
immunology77. It is important, therefore, that we include routine testing of mutations as part of 
existing clinical trial programs in FL and that we equally increase our efforts in understanding the 
functional roles of these inhibitors within the context of complex tumor genetics. 
Lysine specific demethylase inhibitors: a new area of epigenetic therapy 
Despite >80% of FL cases carry KMT2D mutations24, 25, 36, no attempt has been made to target the 
resulting epigenetic abnormalities.24, 26. One therapeutic strategy may be to inhibit lysine 
demethylases (KDMs) that regulate H3K4 methylation, in order to counteract the H3K4 methylation 
imbalance in loss-of-function KMT2D mutants. The KDM family consists of seven subfamilies, with 
the KDM1 and KDM5 families both able to regulate H3K4 methylation. A number of inhibitors of 
these two families have been reported, although neither family has been investigated in lymphoma. 
Several inhibitors of the KDM1 family member LSD1 are currently undergoing clinical trials for other 
malignancies, such as acute myeloid leukemia (TCP78, ORY-1001,79 and GSK287955280). More 
recently, three potent KDM5 inhibitors (EPT-10318281, 82, CPI-455,83 and KDM5-C7084) have been 
reported in pre-clinical studies, all of which demonstrate selectivity over other KDM families, 
increase H3K4me3 levels and cause significant inhibition of cell proliferation in myeloma84 and 
drug-resistant small cell lung cancer83. There is value, therefore, in exploring LSD1 and KDM5 
inhibitors as a means of potentiating a new area of epigenetic therapeutics for KMT2D-mutant FL. 
Conclusion 
The landscape of FL demonstrates a complex pattern of frequent mutations in epigenetic 
modifiers that are co-founding events arising in the CPC and remain stable during disease 
progression and transformation, providing a compelling rationale for using epigenetic therapies. 
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These aberrant epigenetic mechanisms have also been implicated in predicting patient outcomes 
as demonstrated by the m7-FLIPI model, which links 7 mutations, 5 of which with epigenetic 
function, to FL prognosis. While promising, it is yet to be determined whether these mutations can 
be used to robustly stratify patients at diagnosis to inform clinical decision making, and whether 
they have any predictive value in determining response to epigenetic therapy in particular. 
Collectively, our understanding of abnormal epigenetic mechanisms in FL is still at its infancy 
and there are a number of hurdles to overcome if the epigenetic therapies are to realize their full 
potential clinically. From a biological perspective, we need a better understanding on whether the 
aberrant epigenetic modifiers act alone or cooperate in driving the B cell malignancy and what 
functional impact they have on downstream pathways. From the therapeutics perspective, future 
research impetus should focus on determining how these epigenetic therapies exert their effects in 
patients and rationalize treatment combinations in order to maximize their efficacy. Despite the 
challenges, we are in an exciting era of precision medicine where advanced technologies can help 
us routinely characterize the genetic and epigenetic landscape of individual patients for hypothesis-
driven therapeutic strategies whose impact on patient outcomes are being revealed from ongoing 
clinical trials. 
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Table 1. Current clinical trials with investigational EZH2i in B cell malignancies including FL. 
Novel Agent Clinical Trial No Clinical Trial Phase Estimated 
Enrollment 
Eligibility Criteria Trial 
Arms 
Additional 
Remarks 
EPZ-6438 
(Tazemetostat)  
NCT01897571 Phase I 
(closed) 
Phase II 
(recruiting) 
350 Phase I: B-cell 
lymphomas, 
advanced solid 
tumors 
Phase II: DLBCL, 
FL, tFL, PMLBCL 
Phase I: 
single 
arm 
(safety 
study); 
Phase II: 
5 cohorts 
based on 
histology, 
cell of 
origin, 
and 
EZH2 
mutation 
status 
(efficacy 
study) 
 
Phase I 
preliminary 
results: 
9/15 OR
64
 
GSK2816126 NCT02082977 Phase I 
(recruiting) 
169 Relapsed/refractory 
DLBCL, tFL, other 
NHL, MM, solid 
tumors  
Single 
arm 
(safety 
study) 
After RP2D 
is 
established, 
in part 2, 
GCB-
DLBCL, tFL 
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DLBCL; diffuse large B cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma; OR, objective response; PMLBCL, primary mediastinal large B-cell lymphoma; 
RP2D, recommended phase 2 dose; tFL, transformed FL. 
  
and MM 
patients will 
be 
assigned to 
two cohorts 
based on 
EZH2 
mutation 
status. 
Outcome 
data is not 
available. 
CPI-1205 NCT02395601 Phase I 
(recruiting) 
41 B-cell lymphoma Single 
arm 
(safety 
study) 
Outcome 
data not 
available. 
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Table 2. Selected HDACi in phase I/II clinical trials for NHL. 
Agent(s) Clinical Trial 
No 
Clinical Trial Phase Enrollme
nt 
Eligibility Criteria Trial Arms Additional 
Remarks 
Vorinostat NCT002536
30 
Phase II (completed) 37 relapsed/refractor
y indolent NHL 
Single arm 
(safety/effica
cy study) 
ORR: 47% 
FL, 22% 
MZL, 0% 
MCL
70
 
Vorinostat NCT008750
56 
Phase II (active, not 
recruiting) 
54 relapsed/refractor
y indolent NHL 
Single arm 
(safety/effica
cy study) 
ORR: 49% 
FL, 43% 
non-FL 
indolent 
NHL, 0% 
MCL
69
 
Vorinostat 
+ 
Rituximab 
NCT007208
76 
Phase II (active, not 
recruiting) 
33 Indolent NHL Single arm 
(safety/effica
cy study) 
ORR: 50% 
FL and 
MZL, 33% 
MCL
85
 
PCI-24781 
(Abexinosta
t) 
NCT007249
84 
Phase I/II (completed) 55 Phase I:  
relapsed/refractor
y lymphoma 
Single arm 
(safety/effica
cy study) 
ORR: 64% 
FL, MCL: 
27%
86
 
Phase II:  
Relapsed/refract
ory FL, MCL 
Panobinost
at 
NCT012612
47 
Phase II (active, not 
recruiting) 
41 Relapsed/refract
ory NHL 
Single arm 
(efficacy 
study) 
Outcome 
data not 
available. 
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CTCL, cutaneous T cell lymphoma; DLBCL; diffuse large B cell lymphoma; FL, follicular lymphoma; 
MCL, mantle cell lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma; ORR, 
objective response rate; NHL, non-Hodgkin lymphoma. 
  
CUDC-907 
(Dual 
HDAC/PI3K 
inhibitor) 
NCT017429
88 
Phase I (recruiting) 138 
(estimate
d) 
Relapsed/refract
ory lymphoma or 
MM 
CUDC-907 
vs CUDC-
907 + 
Rituximab 
(dose 
escalating 
arms) 
ORR: 55% 
DLBCL, 
0% MM 
and other 
lymphoma
87
 
Mocetinost
at 
NCT022823
58 
Phase I/II (recruiting) 56 
(estimate
d) 
Relapsed/refract
ory DLBCL and 
FL 
(CREBBP/EP300
-mutant) 
Single arm 
(safety/effica
cy study) 
Outcome 
data not 
available. 
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Figure 1. Frequently mutated epigenetic modifiers in FL. Schematic model of recurrent 
mutations affecting epigenetic modifiers in FL with reported frequencies for KMT2D24, 25, 27, 34, 
EZH225, 28, 32, 34, CREBBP25-27, 34, EP30026, 27, 32, 34, linker histone H1 and histone H2 family25, 27, 32, 
SWI/SNF complex members (ARID1A, ARID1B, BCL7A)27, 32, 34, and MEF2B23, 25, 32, 34 depicted 
above. Mutations in epigenetic modifiers occur concurrently in majority of FL patients and 
mechanistically it is not clear whether they act alone or cooperatively in driving B cell malignancy. 
H3Kac, histone H3 lysine acetylation; H3K4me3, histone H3 lysine 4 trimethylation; H3K27me3, 
histone H3 lysine 27 trimethylation. 
